Flow Neuroscience Launches FL-100, First FDA-Approved At-Home tDCS Treatment for Depression in the US

Flow Neuroscience has launched FL-100 in the United States, making it the first FDA-approved at-home transcranial direct current stimulation (tDCS) treatment for moderate to severe major depressive disorder. Available by prescription, FL-100 offers clinicians and patients a new evidence-based treatment option that can be used as monotherapy or alongside medication.